Related Experiment Videos
Prevention of platelet hyperaggregation during coronary angiography
The Journal of International Medical Research
|January 1, 1986
Summary
Coronary angiography may increase platelet aggregation, posing cardiovascular risks. Ticlopidine, a platelet antiaggregating drug, did not prevent these changes in a small study.
Area of Science:
- Cardiovascular medicine
- Hematology
- Pharmacology
Background:
- Coronary angiography is associated with increased platelet aggregation.
- This aggregation may lead to adverse cardiovascular events, including ventricular fibrillation and death.
- Previous research indicated a need for preventative measures.
Purpose of the Study:
- To investigate the efficacy of ticlopidine in preventing post-coronary angiography platelet aggregation.
- To assess the impact of a pre-procedural antiplatelet regimen on circulating platelet aggregates.
Main Methods:
- A study involving ten patients undergoing coronary angiography.
- Patients received the platelet antiaggregating drug ticlopidine five days prior to the procedure.
- Circulating Platelet Aggregates (CPA) test was used to monitor platelet activity.
Main Results:
- No significant changes were observed in the CPA test results for patients treated with ticlopidine.
- The antiplatelet drug did not appear to inhibit the increase in platelet aggregation post-angiography.
Conclusions:
- Ticlopidine administration prior to coronary angiography did not prevent the expected increase in platelet aggregation.
- Further research is needed to identify effective strategies for mitigating cardiovascular risks associated with coronary angiography.